BR0310081A - Diaminotiazóis úteis como inibidores seletivos de cdk4 - Google Patents

Diaminotiazóis úteis como inibidores seletivos de cdk4

Info

Publication number
BR0310081A
BR0310081A BR0310081-2A BR0310081A BR0310081A BR 0310081 A BR0310081 A BR 0310081A BR 0310081 A BR0310081 A BR 0310081A BR 0310081 A BR0310081 A BR 0310081A
Authority
BR
Brazil
Prior art keywords
useful
treatment
diaminothiazoles
control
compounds
Prior art date
Application number
BR0310081-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Xin-Jie Chu
Qingjie Ding
Nan Jiang
Kyungjin Kim
Allen John Lovey
Warren William Mccomas
John Guilfoyle Mullin Jr
Jefferson Wright Tilley
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0310081A publication Critical patent/BR0310081A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/42Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR0310081-2A 2002-05-17 2003-05-12 Diaminotiazóis úteis como inibidores seletivos de cdk4 BR0310081A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38151302P 2002-05-17 2002-05-17
PCT/EP2003/004939 WO2003097048A1 (en) 2002-05-17 2003-05-12 Diaminothiazoles

Publications (1)

Publication Number Publication Date
BR0310081A true BR0310081A (pt) 2005-02-15

Family

ID=29550137

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0310081-2A BR0310081A (pt) 2002-05-17 2003-05-12 Diaminotiazóis úteis como inibidores seletivos de cdk4

Country Status (16)

Country Link
US (1) US6818663B2 (https=)
EP (1) EP1507530B1 (https=)
JP (1) JP4308133B2 (https=)
KR (1) KR100619515B1 (https=)
CN (1) CN100400041C (https=)
AR (1) AR040078A1 (https=)
AT (1) ATE308323T1 (https=)
AU (1) AU2003232754B2 (https=)
BR (1) BR0310081A (https=)
CA (1) CA2485367A1 (https=)
DE (1) DE60302152T2 (https=)
ES (1) ES2251697T3 (https=)
MX (1) MXPA04011372A (https=)
PL (1) PL374581A1 (https=)
RU (1) RU2311414C2 (https=)
WO (1) WO2003097048A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070167329A1 (en) * 2003-12-24 2007-07-19 Bayer Cropscience Gmbh Plant growth regulation
US7211576B2 (en) * 2004-04-20 2007-05-01 Hoffmann-La Roche Inc. Diaminothiazoles
US7405220B2 (en) 2004-06-09 2008-07-29 Hoffmann-La Roche Inc. Pyrazolopyrimidines
US7705009B2 (en) * 2005-11-22 2010-04-27 Hoffman-La Roche Inc. 4-aminopyrimidine-5-thione derivatives
CA2668210C (en) 2006-10-31 2013-03-12 Schering Corporation Anilinopiperazine derivatives and methods of use thereof
AR063531A1 (es) 2006-10-31 2009-01-28 Schering Corp Derivados de anilinopiperazina y composicion farmaceutica
US8502401B2 (en) * 2008-08-12 2013-08-06 Delsper LP Polymeric compositions comprising per(phenylethynyl) arene derivatives
ES2718637T3 (es) * 2010-08-24 2019-07-03 Gtx Inc Compuestos para el tratamiento del cáncer
WO2013074120A1 (en) 2011-11-18 2013-05-23 Greene, Tweed & Co. Crosslinking compounds for high glass transition temperature polymers
CA2909683A1 (en) 2013-04-16 2014-10-23 Memorial Sloan-Kettering Cancer Center Companion diagnostic for cdk4 inhibitors
WO2015051525A1 (en) * 2013-10-11 2015-04-16 Rhodia Operations Synthesis of acetal/ketal
WO2017156263A1 (en) 2016-03-09 2017-09-14 Memorial Sloan-Kettering Cancer Center Enigma and cdh18 as companion diagnostics for cdk4 inhibitors
WO2017158147A1 (en) 2016-03-18 2017-09-21 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2018089902A1 (en) * 2016-11-13 2018-05-17 Apogee Biotechnology Corporation Diaminothiazole compounds, compositions and methods of use
CN110950848B (zh) * 2018-09-27 2024-03-26 徐诺药业 新型氨基吡唑类衍生物的合成与应用
AU2020266083A1 (en) 2019-04-30 2021-09-23 Instituto de Medicina Molecular João Lobo Antunes Rank pathway inhibitors in combination with CDK inhibitors
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2714059B1 (fr) * 1993-12-21 1996-03-08 Sanofi Elf Dérivés amino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
NZ503788A (en) * 1997-10-27 2002-11-26 Agouron Pharma 4-aminothiazole derivatives and their use as inhibitors of cyclin-dependent kinases
UA71971C2 (en) * 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
EP1307462A2 (en) * 2000-08-09 2003-05-07 Agouron Pharmaceuticals, Inc. Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclin-dependent kinases
US6756374B2 (en) 2001-01-22 2004-06-29 Hoffmann-La Roche Inc. Diaminothiazoles having antiproliferative activity

Also Published As

Publication number Publication date
RU2311414C2 (ru) 2007-11-27
JP4308133B2 (ja) 2009-08-05
CA2485367A1 (en) 2003-11-27
WO2003097048A1 (en) 2003-11-27
AU2003232754A1 (en) 2003-12-02
CN1652780A (zh) 2005-08-10
RU2004137110A (ru) 2005-08-20
AR040078A1 (es) 2005-03-16
US6818663B2 (en) 2004-11-16
KR20050006261A (ko) 2005-01-15
KR100619515B1 (ko) 2006-09-08
PL374581A1 (en) 2005-10-31
ES2251697T3 (es) 2006-05-01
DE60302152T2 (de) 2006-07-13
DE60302152D1 (de) 2005-12-08
JP2005530783A (ja) 2005-10-13
US20040006058A1 (en) 2004-01-08
ATE308323T1 (de) 2005-11-15
EP1507530B1 (en) 2005-11-02
AU2003232754B2 (en) 2009-03-12
EP1507530A1 (en) 2005-02-23
MXPA04011372A (es) 2005-08-15
CN100400041C (zh) 2008-07-09

Similar Documents

Publication Publication Date Title
BR0310081A (pt) Diaminotiazóis úteis como inibidores seletivos de cdk4
BR0315912A (pt) Compostos pirimìdicos com atividade antiproliferativa (ii)
BRPI0409366A (pt) compostos de pirimido
García-Echeverría Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment
NO20090631L (no) Morpholin pyrimidin derivativer anvendelige i behandlingen av proliferative lidelser
BRPI0606107A2 (pt) compostos farmacêuticos, seus proocessos de preparação, usos dos mesmos na fabricação de medicamento e composição farmacêutica compreendendo os referidos compostos
BRPI0518126A (pt) composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito inibitório de b-raf e um efeito anti-cáncer em um animal de sangue quente, e para tratar uma doença ou condição
ES2953005T3 (es) Tratamiento para el cáncer
MX2007010072A (es) Derivados de piperidina antibacterianos.
BRPI0507644A (pt) pirazolopirimidinas como inibidores de cinase dependente de ciclina
BRPI0616987A2 (pt) pirazolopirimidinas como inibidores de cinase dependente de ciclina
BRPI0512588A (pt) derivados de uréia de pirimidina como inibidores de cinase
NO20053775L (no) Diazepinoindol derivater som kinaseinhibitorer.
NO20085217L (no) Effektive pyrimidinderivater i behandlingen av kreft
BRPI0511975A (pt) pirazolopirimidinas
WO2002057261A3 (en) Diaminothiazoles and their use as inhibitors of cyclin-dependent kinase
MXPA06000302A (es) Derivados de pirazolil-indol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden.
NO20083250L (no) Antibakterielle pyrrolopyridiner, pyrrolopyrimidiner og pyrroloazepiner
WO2012146933A1 (en) Cyprodinil for use in medicine
TW200510392A (en) Chemical compounds
US20240293557A1 (en) Proteolysis targeting chimeras and methods of use thereof
Pinto-Leite et al. mTOR inhibitors in urinary bladder cancer
TW200624431A (en) Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
EP2408776B1 (en) Use of a kinase inhibitor for the treatment of thymoma
BRPI0407381A (pt) 4-aminopirimidino-5-ona

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 8A. ANUIDADES(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 8A E 9A ANUIDADES.